Scleroderma Treatment Market

The increasing exposure to risk factors such as exposure to silica, aromatic and chlorinated solvents, ketones, welding fumes and the development of advanced high sensitive and selective skin biopsy and blood tests is driving a large market growth. The high recurrence and expanse of the disease to systemic resulting in death due to heart, lung, and gastrointestinal complications is driving a large market owing to low elasticity of demand. The incidence of systemic Scleroderma is estimated to be around 3 for every 100,000 people per year. The growing geriatric population is another driver of the market as Scleroderma most often begins in middle age.

However, factors restraining the Scleroderma treatment market include lack of curative treatment, poor efficacy and efficiency of present drug regimens, and others.

Scleroderma Treatment Market: Overview

Based on regions, the global scleroderma treatment market is classified into North America, Latin America, Europe, CIS & Russia, Japan, Asia-Pacific excluding Japan (APEJ) and the Middle East & Africa (MEA). North America is expected to account for the largest share in the global Scleroderma treatment market owing to growth in the income of women, large investments by pharmaceutical companies and the huge potential of the market.

The scleroderma Treatment markets in Europe is expected to be led by Germany, France and the UK. China and India are expected to drive the lion’s share in the Asia Pacific Scleroderma treatment market.

The Middle East and Africa Scleroderma Treatment market is expected to be driven by the gulf economies of Saudi Arabia, Kuwait and Qatar. However, poor per capita income of African countries is likely to hamper the Scleroderma Treatment market growth in this region.

Scleroderma Treatment Market: Key Players

Some of the major players in the global Scleroderma Treatment market are Cumberland Pharmaceuticals, Inc., Gilead Sciences, Inc., Pfizer, Inc., Sanofi, Boehringer Ingelheim International GmbH, Corbus Pharmaceuticals Holdings, Inc., Actelion Pharmaceuticals, Inc.,, Bayer AG, Cytori Therapeutics, Inc., and others.

This market study is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The study provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The study also maps the qualitative impact of various market factors on market segments and geographies.

The market study covers exhaustive analysis on:

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain

Regional analysis includes

• North America
  • US
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Peru
  • Rest of LATAM
• Europe
  • EU – 4 (Germany, France, Italy, Spain)
  • UK
  • BENELUX (Belgium, Netherlands, Luxemburg)
  • NORDIC (Norway, Denmark, Iceland, Sweden)
  • Eastern Europe (Poland, Ukraine, Czech Rep. etc.)
  • Rest of Europe
• CIS & Russia
• Japan
• APEJ
  • Greater China
  • India
  • Korea
  • ASEAN Countries
  • Rest of APEJ
• Middle East & Africa
  • GCC Countries
  • Turkey
  • Iran
  • Israel
  • South Africa
  • Rest of MEA